University of Nebraska Medical Center (NEUN)
Welcome,         Profile    Billing    Logout  
 3 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lowes, Brian D
NCT03644667: Tocilizumab in Cardiac Transplantation

Active, not recruiting
2
385
US
tocilizumab, Actemra®, Placebo, Placebo for tocilizumab, Placebo for Actemra®, Standard of Care Triple IS, calcineurin inhibitor: (tacrolimus (Prograf ®)), anti-proliferative treatment: (mycophenolate mofetil ),, MMF, CellCept®, Myfortic®, enteric-coated mycophenolate sodium, steroids: methylprednisolone/prednisone
National Institute of Allergy and Infectious Diseases (NIAID), PPD
Heart Transplant
04/25
04/25
Shields, Kimberly
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
04/25
12/25
BTCRC-LUN18-153, NCT04317534: Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Recruiting
2
244
US
Pembrolizumab
Greg Durm, MD, Merck Sharp & Dohme LLC
NSCLC, Stage I
04/26
04/29
NCT03644667: Tocilizumab in Cardiac Transplantation

Active, not recruiting
2
385
US
tocilizumab, Actemra®, Placebo, Placebo for tocilizumab, Placebo for Actemra®, Standard of Care Triple IS, calcineurin inhibitor: (tacrolimus (Prograf ®)), anti-proliferative treatment: (mycophenolate mofetil ),, MMF, CellCept®, Myfortic®, enteric-coated mycophenolate sodium, steroids: methylprednisolone/prednisone
National Institute of Allergy and Infectious Diseases (NIAID), PPD
Heart Transplant
04/25
04/25
NCT04748419: Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

Recruiting
1/2
43
US
consolidative hypofractionated radiation therapy (hfRT), Durvalumab 50 MG/ML, Imfinzi
University of Nebraska, AstraZeneca
Lung Cancer, Carcinoma, Non-Small Cell Lung
03/26
03/26

Download Options